ALKS
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.25B
GET INTRADAY SIGNALS
ALKS Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
34 days until earnings call
+Compare
ALKS
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.25B

ALKS Price Prediction, Alkermes plc AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ALKS Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

ALKS's Indicator enters downward trend

The Aroon Indicator for ALKS entered a downward trend on March 23, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 155 similar instances where the Aroon Indicator formed such a pattern. In 118 of the 155 cases the stock moved lower. This puts the odds of a downward move at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 15, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALKS moved below its 50-day moving average on March 07, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALKS crossed bearishly below the 50-day moving average on March 08, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ALKS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.055) is normal, around the industry mean (6.765). P/E Ratio (0.000) is within average values for comparable stocks, (48.055). ALKS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.964). ALKS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (3.788) is also within normal values, averaging (87.845).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALKS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

ALKS is expected to report earnings to fall 107.14% to 0 cents per share on April 27

Alkermes plc ALKS Stock Earnings Reports
Q1'23
Est.
$-0.01
Q4'22
Beat
by $0.09
Q3'22
Missed
by $0.01
Q2'22
Beat
by $0.05
Q1'22
Beat
by $0.09
The last earnings report on February 16 showed earnings per share of 14 cents, beating the estimate of 5 cents. With 132.29K shares outstanding, the current market capitalization sits at 4.25B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.1B. The market cap for tickers in the group ranges from 246 to 77.31B. MKKGY holds the highest valuation in this group at 77.31B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -5%. VFRM experienced the highest price growth at 54%, while CHALF experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 55
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1 Burlington Road
Phone
+353 17728000
Employees
2280
Web
https://www.alkermes.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EAOM25.000.05
+0.19%
iShares ESG Aware Moderate Allc ETF
FDT48.990.04
+0.08%
First Trust Dev Mkts Ex-US AlphaDEX® ETF
DLN59.37-0.16
-0.27%
WisdomTree US LargeCap Dividend ETF
SPVU38.09-0.34
-0.89%
Invesco S&P 500® Enhanced Value ETF
ALTY10.95-0.11
-0.99%
Global X Alternative Income ETF

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with DCPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then DCPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-0.31%
DCPH - ALKS
41%
Loosely correlated
-0.67%
NBIX - ALKS
39%
Loosely correlated
+0.57%
SUPN - ALKS
37%
Loosely correlated
-1.02%
DVAX - ALKS
36%
Loosely correlated
+1.66%
ANIP - ALKS
36%
Loosely correlated
-2.43%
More